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Abstract 
The strongest genetic risk factor for Alzheimer’s disease (AD) is the Apolipoprotein E type 4 allele (ApoE 
ε4). The interaction between sex and ApoE ε4 carrier status on AD risk remains an area of intense 
investigation. We hypothesized that sex modulates the relationship between ApoE ε4 carrier status and 
brain tau deposition (a quantitative endophenotype in AD) in individuals with mild cognitive impairment 
(MCI).  
Methods: Preprocessed 18F-AV-1451 tau and 18F-AV-45 amyloid PET images, T1-weighted structural 
magnetic resonance imaging (MRI) scans, demographic information, and cerebrospinal fluid (CSF) 
total tau (t-tau) and phosphorylated tau (p-tau) measurements from 108 MCI subjects in the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database were included. After downloading pre-processed 
images from ADNI, an iterative reblurred Van Cittertiteration partial volume correction (PVC) method 
was applied to all PET images. MRIs were used for PET spatial normalization. Regions of interest (ROIs) 
were defined in standard space, and standardized uptake value ratio (SUVR) images relative to cerebellum 
were computed. ApoE ε4 by sex interaction analyses on 18F-AV-1451 and CSF tau (t-tau, p-tau) were 
assessed using generalized linear models. The association between 18F-AV-1451 SUVR and CSF tau (t-tau, 
p-tau) was assessed.  
Results: After applying PVC and controlling for age, education level and global cortical 18F-AV-45 SUVR, 
we found that the entorhinal cortex, amygdala, parahippocampal gyrus, posterior cingulate, and occipital 
ROIs exhibited a significant ApoE ε4 by sex interaction effect (false discovery rate P < 0.1) among MCI 
individuals. We also found a significant ApoE ε4 by sex interaction effect on CSF t-tau and p-tau. 
18F-AV-1451 SUVR in the 5 ROIs with ApoE ε4 by sex interaction was significantly correlated with CSF 
p-tau and t-tau. 
Conclusions: Our findings suggest that women are more susceptible to ApoE ε4-associated 
accumulation of neurofibrillary tangles in MCI compared to males. Both CSF tau (p-tau, t-tau) and brain 
tau PET are robust quantitative biomarkers for studying ApoE ε4 by sex effects on brain tau deposition in 
MCI participants. 
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Introduction 
Alzheimer’s disease (AD) is the leading cause of 
dementia in the elderly. AD is characterized by the 
presence of amyloid β (Aβ) plaques and 
hyperphosphorylated tau neurofibrillary tangles 
(NFT) which are thought to be responsible for 
neurodegeneration and subsequent cognitive 
dysfunction. The lack of therapies for AD highlights 
the clinical need to better understand the 
environmental, genetic, and demographic risk factors 
underlying disease risk and progression. 
Apolipoprotein E type 4 allele (ApoE ε4) is the largest 
genetic risk factor for AD development [1, 2]. ApoE ε4 
carriers exhibit faster cognitive decline [3, 4], 
increased amyloid β deposition [5], higher NFT 
density [6] and increased glucose hypometabolism [7] 
than ApoE ε4 non-carriers. In addition to genetics, sex 
is an important demographic factor that influences 
AD risk. Compared to males, females are reported to 
have higher incidence of AD [8], worse cognitive 
functions when they have AD [9], and increased AD 
pathology [10, 11]. The interaction between sex and 
ApoE ε4 carrier status on cognitive decline remains an 
area of intense investigation. Sex has been shown to 
modulate the effects of ApoE ε4 in AD clinical 
conversion risk. Strikingly, healthy older females and 
females with mild cognitive impairment (MCI) who 
carry the ApoE ε4 allele are more likely to develop AD 
than their male counterparts [12, 13]. Female ApoE ε4 
carriers exhibit higher tau levels in the cerebrospinal 
fluid (CSF) compared to male carriers [13], especially 
among amyloid positive females [14].  
Neuroimaging shows promise in early AD 
diagnosis. The novel PET tracer 18F-AV-1451 (also 
called 18F-T807, 18F-flortaucipir) showed higher 
selectivity of >25 fold for paired helical filaments of 
hyperphosphorylated tau (PHF-tau) compared to 
amyloid β [15]. The 18F-AV-1451 radiotracer displays 
favorable pharmacokinetic properties, good overlap 
with PHF-tau deposits as described by Braak staging 
[16], and strong association with dementia severity 
[17]. These characteristics make 18F-AV-1451 a useful 
imaging biomarker for studying AD and dementia.  
The analysis of ApoE ε4 by sex interaction in tau 
PET imaging is critical for understanding the role of 
sex and ApoE ε4 on brain tau PET as a quantitative 
AD endophenotype. Uncovering regions with ApoE 
by sex interaction in MCI patients will also help in the 
development of precision-medicine therapies targeted 
to sex and ApoE-stratified patient groups in MCI. 
Further, this analysis will also help to define more 
appropriate sex and ApoE-stratified imaging-based 
endpoints for clinical trials in AD. In this study we 
examined whether sex modulates the ApoE ε4 effect 
on brain tau deposition measured by 18F-AV-1451 PET 
among MCI subjects in the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI).  
Methods 
Participants 
In this cross-sectional study, we collected 
subjects with available ApoE ε4 genotyping 
information and 18F-AV-1451 PET, 18F-AV-45 PET and 
T1-weighted structural magnetic resonance imaging 
(MRI) scans from ADNI. 108 MCI subjects were 
included. For every subject, only his or her most 
recent 18F-AV-1451 PET and matched T1-weighted 
MRI scan in the same scanning visit were included. 
The most recent 18F-AV-45 PET scan was also 
included for each subject.  
All MCI subjects had a subjective memory 
concern reported by a clinician, abnormal memory 
function on the education-adjusted Logical Memory II 
subscale, and a clinical dementia rating of 0.5 or 
higher. Further, all MCI subjects were deemed to have 
cognitive and functional performance that was 
sufficiently intact to not merit a diagnosis of dementia 
by the site physician. 
A full list of study inclusion/exclusion criteria 
can be found at https://adni.loni.usc.edu/wp- 
content/uploads/2008/07/adni2-procedures-manual
.pdf.  
ApoE Genotyping, CSF Aβ, t-tau, and p-tau 
Assessments 
Peripheral blood (10 mL) was collected from 
study participants to be used for ApoE ε4 genotyping. 
Restriction enzyme isoform genotyping was 
performed on extracted DNA to test for the presence 
of the ApoE ε4 genotype, as described previously [18]. 
ApoE ε4 carriers were defined as individuals with at 
least one ε4 allele (either ε4/ ε4, ε4/ ε3 or ε4/ ε2). 
Non-carriers were defined as individuals with no ε4 
allele. 
CSF samples were acquired through lumbar 
puncture as previously described by ADNI: 
http://adni.loni.usc.edu/methods/documents/. 
Concentration of CSF biomarkers including Aβ, t-tau, 
and p-tau, were assessed using the xMAP Luminex 
platform (Luminex Corp., Austin, TX) platform. For 
more details regarding CSF specimen collection and 
analyte measurement please refer to ADNI. 
MRI and PET Acquisition and Processing 
T1-weighted MRI and pre-processed 
18F-AV-1451 and 18F-AV-45 PET images were 
downloaded from the ADNI database 
(http://adni.loni.usc.edu/). The PET images had 
been previously aligned, averaged, reoriented and 
then interpolated into a standard image and voxel size 
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(image volume 160×160×96, 1.5×1.5×1.5 mm in x, y, 
z), and smoothed to a uniform resolution of 8 mm in 
full width at half maximum (FWHM) by the ADNI 
consortium.  
We further processed the downloaded PET 
images using Statistical Parametric Mapping (SPM12, 
Wellcome Department of Imaging Neuroscience, 
London, United Kingdom) and MATLAB (The 
MathWorks Inc.). Briefly, all PET images were 
coregistered to matched structural MRI images. The 
MRI images were normalized to standard Montreal 
Neurologic Institute (MNI) space using SPM12 and 
VBM8 toolbox with a MRI template (image volume: 
121×145×121, voxel size: 1.5×1.5×15 mm in x, y, z). 
The transformation parameters determined by MRI 
spatial normalization were then applied to the 
coregistered PET images for PET spatial 
normalization. Regions of interest (ROIs) including 
cerebellum gray matter for reference tissue were 
manually drawn on the MRI template using PMOD 
(PMOD Technologies Ltd., Zürich, Switzerland) in 
standard MNI space. ROI templates developed 
previously in the Johns Hopkins Department of 
Radiology were used in this study [7, 19-21]. To 
measure whole brain amyloid deposition, a global 
cortex was defined as a union of orbital frontal, 
prefrontal, superior frontal, lateral temporal, parietal, 
posterior precuneus, occipital, anterior cingulate, and 
posterior cingulate. Standard uptake value ratio 
(SUVR) images were calculated relative to the 
cerebellum. ROI SUVRs were obtained by calculating 
mean SUVR within ROIs on the SUVR images in the 
MNI space.  
A partial volume correction (PVC) was applied 
to the processed 18F-AV-1451 and 18F-AV-45 PET 
images to correct or minimize potential 
underestimation in PET measurement due to low 
image resolution, especially for small tissues as the 
amygdala and striatum. In brief, an iterative reblurred 
Van Cittertiteration method was used for PVC on the 
mean images, where a 3-D Gaussian kernel of 8 mm 
FWHM was used for spatial smoothing function h, 
step length α=1.5, and the iteration was stopped if 
relative percent change of PVC images < 1% [22].  
Statistical Analysis 
To increase statistical power, a ROI feature 
selection method was used to select regions of interest 
for ApoE by sex interaction analyses. Specifically, we 
selected 13 cortical and subcortical regions including 
the entorhinal cortex, amygdala, fusiform, 
parahipppocampal gyrus, occipital, lateral temporal, 
parietal, posterior precuneus, posterior cingulate, 
orbital frontal cortex, prefrontal cortex, superior 
frontal, and anterior cingulate, using ROI templates 
we developed previously in the Johns Hopkins 
Department of Radiology [7, 19-21]. These 13 regions 
were either previously determined by our group to 
significantly differ in 18F-AV-1451 PET SUVR between 
cognitively normal, MCI and AD patients [23] or were 
required to define global cortical amyloid [19]. All 
false discovery rate (FDR) corrections were applied 
using these 13 ROIs. A depiction of the 13 ROIs used 
in the study are presented in MNI space in Figure S1 
in the Supplement. 
Statistical Analysis System (SAS version 9.4, SAS 
Institute, Inc) was used for all statistical analyses. Two 
generalized linear models (GLMs) with and without 
controlling for global cortical 18F-AV-45 SUVR were fit 
for ApoE ε4 carrier status by sex interaction analyses:  
ROI_SUVR (18F-AV-1451) ~ Age + Educational level + 
Global cortex_SUVR (18F-AV-45) + Sex:ApoE ε4 status 
ROI_SUVR (18F-AV-1451) ~ Age + Educational level + 
Sex:ApoE ε4 status 
The GLM models were fit for each ROI SUVR 
and the ApoE ε4 by sex term was evaluated to identify 
regions with significant ApoE ε4 by sex interaction 
effect on 18F-AV-1451 uptake. P values of ApoE ε4 by 
sex term were corrected for multiple comparisons 
using a Benjamini-Hochberg method with FDR < 10% 
defined as significant, consistent with previous 
studies [24-26] . 
Estimated marginal means (LS-means) of ApoE 
ε4 carriers and non-carriers stratified by sex were 
calculated using the interactive models in order to 
investigate the effects of ApoE ε4 on 18F-AV-1451 in 
women and men separately. Differences in LS-means 
between ApoE ε4 carriers and non-carriers in males 
and females separately were evaluated. In addition, 
we also evaluated differences in LS-means between 
males and females in ApoE ε4 carrier and non-carrier 
groups separately. P values were corrected for 
multiple comparisons using the Tukey-Kramer 
method [27] (maximum experimentwise error rate P 
<0.05).  
Similar to the brain tau PET analyses, ApoE ε4 by 
sex interaction effects on CSF t-tau and p-tau were 
analyzed by fitting a GLM and controlling for age and 
education level. We fit additional models controlling 
for either global cortical 18F-AV-45 amyloid SUVR or 
CSF amyloid.  
To investigate whether the regional 18F-AV-1451 
was significantly associated with AD-relevant 
biomarkers such as CSF t-tau and p-tau, the 
correlation between CSF tau (t-tau, p-tau) and 
regional 18F-AV-1451 was analyzed by linear 
regression. 
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Data Availability 
All datasets used during the current study are 
available in the ADNI repository, 
http://adni.loni.usc.edu/. 
Results 
Cohort Characteristics  
A total of 108 ADNI subjects (38 ApoE ε4 carriers 
and 70 ApoE ε4 non-carriers; 42 women and 66 men) 
were included in the study. Participant characteristics 
are summarized in the Table 1. The mean±SD age of 
our study participants was 78 ± 7.4 years. No 
significant differences in age, MMSE score, and global 
cortical amyloid SUVR were found between women 
and men in the ApoE ε4 carrier (two-sample t-test P > 
0.05) and non-carrier groups (two-sample t-test P > 
0.05). A moderate difference in education level was 
found between women and men in the ApoE ε4 
carriers (two-sample t-test P = 0.01) and non-carriers 
(two-sample t-test P =0.02) groups. Chi-squared 
analysis revealed no significant differences in the 
proportion of ApoE ε4ε4/ ε4ε3/ ε4ε2 genotype 
individuals between men and women (P = 0.38). A 
full list of demographic variables with statistics are 
listed in Table 1.  
ApoE ε4 by sex interaction on 18F-AV-1451 
ROI SUVR 
ROIs with significant ApoE ε4 by sex interaction 
on 18F-AV-1451 SUVR were identified with and 
without controlling for global cortical amyloid (Table 
2) using the 13 ROIs described in the Methods. In MCI 
individuals, we found the entorhinal cortex, 
amygdala, parahippocampal gyrus, posterior 
cingulate, and occipital ROIs to exhibit a significant 
ApoE ε4 carrier status by sex effect (FDR P < 0.1) after 
applying PVC and controlling for global cortical 
amyloid uptake measured by 18F-AV-45 PET. Notably, 
only the entorhinal cortex reached significance (FDR P 
< 0.1) in the non-PVC data (Table 2). For the GLM 
without controlling for global cortical amyloid 
uptake, we found the entorhinal cortex, amygdala, 
fusiform, parahippocampal gyrus, posterior 
cingulate, and occipital ROIs to exhibit a significant 
ApoE ε4 by sex effect (FDR P < 0.1; Table 2) in both 
PVC and non-PVC data. 
Mean SUVR images with and without PVC from 
MCI females and males are displayed in Figure 1. 
Figure 1A visually suggests that PVC increases 
18F-AV-1451 SUVR contrast between ApoE ε4 carriers 
and non-carriers in the entorhinal cortex, amygdala, 
fusiform, parahippocampal gyrus, posterior 
cingulate, and occipital ROIs compared to non-PVC 
mean SUVR images (Figure 1B). Figure 1 also 
suggests that presence of the ApoE ε4 allele is 
associated with more tau deposition in women 
compared to men. Quantified SUVR from 18F-AV-1451 
images with PVC in ROIs stratified by sex and ApoE 
status are displayed in Figure 2. 
 
Table 1. Study cohort characteristics 
 Mean±SD [Range] P valuea 
Characteristic Women 
ApoE ε4+ 
(n=15) 
Women 
ApoE ε4 – 
(n=27) 
Men 
ApoE ε4+ 
(n=23) 
Men 
ApoE ε4 – 
(n=43) 
Women Men ApoE ε4+ ApoE ε4 - 
ε4+ vs ε4 - ε4+ vs ε4 - Women vs Men Women vs Men 
Age, year 74.4±6.8 
[61.2-84.5] 
79.3±6.4 
[68.1-92.6] 
76.7±8.4 
[59.6-90.3] 
79.8±7.1 
[67.8-93.2] 
0.03 0.12 0.39 0.78 
Education, years 14.1±2.7 
[8.0-20.0] 
15.4±2.5 
[12.0-19.0] 
16.8±3.2 
[12.0-20.0] 
17.0±2.9 
[8.0-20.0] 
0.12 0.76 0.01 0.02 
White race, No (%) 15(100) 24(89) 22(96) 43(100) 0.18 0.17 0.41 0.03 
MMSE Score 26.8±2.4 
[23.0-30.0] 
28.0±2.4 
[19.0-30.0] 
27.4±2.6 
[22.0-30.0] 
28.1±2.0 
[23.0-30.0] 
0.13 0.22 0.45 0.80 
global cortical amyloid SUVR 1.56±0.35 
[1.02-2.35] 
1.20±0.21 
[0.96-1.69] 
1.47±0.35 
[0.99-2.20] 
1.28±0.40 
[0.91-3.12] 
0.001 0.06 0.43 0.28 
CSF Aβ-42 (pg/mL) 933.0±398.1 
[469.0-1700] 
1326.6±425.4 
[426-1700] 
845.3±435.0 
[248.1-1700] 
1272.3±415.6 
[396.6-1700] 
0.01 <0.001 0.55 0.62 
CSF t-tau (pg/mL) 380.5±160.8 
[234.6-750.0] 
248.5±89.2 
[100.2-443.5] 
262.7±82.4 
[115.4-426.4] 
240.7±103.2 
[121.4-553.5] 
0.01 0.41 0.03 0.75 
CSF p-tau (pg/mL) 36.5±16.6 
[20.6-71.6] 
21.6±7.9 
[8.7-38.6] 
24.9±8.3 
[10.5-42.3] 
21.6±10.2 
[9.9-52.3] 
0.01 0.22 0.03 1 
Interval between 18F-AV-1451 
and 18F-AV-45, month 
5.5±7.3 
[0.0-27.0] 
4.3±5.1 
[0.0-16.0] 
3.78±4.51 
[0.0-13.0] 
3.30±4.85 
[0.0-17.0] 
0.54 0.70 0.37 0.40 
ε4 ε4/ ε4 ε3/ ε4 ε2 in 
ApoE ε4 carriers 
3/11/1  7/16/0    0.38  
a P value was defined using a two-sample t test to compare age, education level, MMSE Score, global cortical amyloid SUVR, CSF biomarkers and AV1451-AV45 scanning 
interval between ApoE ε4 carriers and ApoE ε4 non-carriers in male and female subgroups, and between males and females in ApoE ε4 carrier and ApoE ε4 non-carrier 
subgroups. A Chi-square test was used to compare differences in proportion of Caucasian participants between ApoE ε4 carriers and ApoE ε4 non-carriers in male and 
female subgroups, and between males and females in ApoE ε4 carrier and ApoE ε4 non-carrier subgroups. A Chi-squared test was used to compare proportion of ε4ε4/ ε4ε3/ 
ε4ε2 genotype individuals between males and females in the ApoE ε4 carrier group. 
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Table 2. ApoE ε4 carrier status by sex interaction effect in MCI participants 
  PVC non-PVC 
Model Characteristic Standardized 
β(95%CI) a 
ApoE ε4 x sex 
P value b 
ApoE ε4 x sex 
Adjusted P valuec  
Standardized 
β(95%CI) a 
ApoE ε4 x sex 
P value b 
ApoE ε4 x sex 
Adjusted P valuec 
Adjusted for 
global cortical  
amyloid level 
Entorhinal Cortex 0.39(0.14-0.64) 0.003 0.03  0.34(0.10-0.59) 0.01 0.09  
Amygdala 0.30(0.03-0.55) 0.03 0.07  0.26(0.00-0.52) 0.05 0.16  
Fusiform 0.25(0.00-0.50) 0.05 0.11  0.21(-0.04-0.46) 0.10 0.22  
Parahippocampal 0.29(0.03-0.54) 0.03 0.07  0.26(0.01-0.51) 0.04 0.16  
Posterior Cingulate 0.31(0.04-0.57) 0.03 0.07  0.25(-0.02-0.51) 0.07 0.18  
Occipital 0.34(0.09-0.58) 0.01 0.06  0.30(0.05-0.55) 0.02 0.11  
Orbital Frontal 0.16(-0.12-0.45) 0.25 0.33  0.06(-0.23-0.340 0.68 0.74  
Prefrontal 0.07(-0.2-0.35) 0.61 0.66  0.03(-0.25-0.31) 0.83 0.83  
Superior Frontal 0.01(-0.26-0.28) 0.96 0.96  -0.07(-0.34-0.20) 0.59 0.70  
Lateral Temporal  0.18(-0.07-0.43) 0.15 0.22  0.15(-0.10-0.40) 0.24 0.40  
Parietal 0.18(-0.07-0.45) 0.15 0.22  0.13(-0.13-0.39) 0.33 0.44  
Posterior Precuneus 0.21(-0.07-0.48) 0.14 0.22  0.16(-0.11-0.43) 0.24. 0.40  
Anterior Cingulate -0.11(-0.38-0.16) 0.42 0.50 -0.13(-0.41-0.14) 0.34 0.44  
Not adjusted for 
global cortical  
amyloid level 
Entorhinal Cortex 0.43(0.18-0.69) 0.001 0.01  0.40(0.14-0.65) 0.003 0.04  
Amygdala 0.34(0.07-0.60) 0.01 0.03  0.30(0.04-0.56) 0.03 0.09  
Fusiform 0.31(0.05-0.58) 0.02 0.05  0.28(0.00-0.55) 0.04 0.10  
Parahippocampal 0.35(0.08-0.61) 0.01 0.03  0.32(0.06-0.59) 0.02 0.08  
Posterior Cingulate 0.35(0.08-0.63) 0.01 0.03  0.30(0.02-0.57) 0.04 0.09  
Occipital 0.40(0.14-0.67) 0.003 0.02  0.37(0.10-0.64) 0.01 0.04  
Orbital Frontal 0.19(-0.09-0.47) 0.19 0.25  0.09(-0.20-0.37) 0.55 0.65  
Prefrontal 0.10(-0.18-0.39) 0.46 0.53  0.07(-0.22-0.35) 0.64 0.69  
Superior Frontal 0.06(-0.22-0.34) 0.67 0.67  -0.01(-0.30-0.27) 0.93 0.93  
Lateral Temporal 0.26(-0.01-0.53) 0.06 0.12  0.22(-0.05-0.49) 0.11 0.20  
Parietal 0.24(-0.03-0.51) 0.08 0.12  0.19(-0.09-0.46) 0.18 0.26  
Posterior Precuneus 0.25(-0.03-0.52) 0.08 0.12  0.21(-0.07-0.48) 0.15 0.24  
Anterior Cingulate -0.09(-0.36-0.17) 0.49 0.53  -0.11(-0.39-0.16) 0.43 0.56  
a β value is coefficient of ApoE ε4 by sex interaction, 95% CI represents the 95% confidence interval of the ApoE ε4 by sex coefficient. 
b P value as defined using a generalized linear model to detect significant ApoE ε4 by sex interaction effect in MCI subjects. Age and education were included as covariates. 
Global cortical amyloid SUVR was also included as a covariate in the upper results. 
c Adjusted P value as defined using Benjamini–Hochberg procedure to control FDR. 
 
Upon comparing SUVR from ApoE ε4 carriers 
with ApoE ε4 non-carriers, we found a significant 
ApoE ε4 effect in the entorhinal cortex, amygdala, 
fusiform, parahippocampus, posterior cingulate, 
occipital cortex, lateral temporal, parietal, and 
posterior precuneus among women (two-sample 
t-test, P < 0.05). In contrast, no ROIs exhibit a 
significant ApoE ε4 effect in men.  
ApoE ε4 and sex-stratified analysis 
Given that we saw significant ApoE ε4 by sex 
interaction effects in MCI patients, we analyzed the 
effect of ApoE ε4 on 18F-AV-1451 stratified by sex 
(Table 3) after adjusting for education, age and 
amyloid. Specifically, we analyzed the difference in 
marginal means between ApoE ε4 carriers and 
non-carriers stratified by sex. All 5 ROIs (entorhinal 
cortex, amygdala, parahippocampal gyrus, posterior 
cingulate and occipital ROIs) with significant ApoE ε4 
by sex interaction effect displayed a significant ApoE 
ε4 effect in women when the marginal means were not 
adjusted for global cortical 18F-AV-45 SUVR. The 
entorhinal cortex, amygdala, parahippocampal gyrus, 
and posterior cingulate retained a significant ApoE ε4 
effect in women when the marginal means were 
adjusted for global cortical 18F-AV-45 SUVR (FDR < 
0.1). No ROIs exhibit a significant ApoE ε4 effect in 
men.  
We also analyzed the difference in marginal 
means between males and females stratified by ApoE 
ε4 carrier status (Table 3). Four out of the 5 ROIs 
(entorhinal cortex, parahippocampal gyrus, posterior 
cingulate and occipital ROIs) with significant ApoE ε4 
by sex interaction showed a significant sex effect in 
ApoE ε4 carriers with or without adjusting marginal 
means for global cortical 18F-AV-45 SUVR. These 
regions retained a significant sex effect in ApoE ε4 
carriers when adjusted for global cortical 18F-AV-45 
SUVR. In contrast, no ROIs exhibit a significant sex 
effect in ApoE ε4 non-carriers. Non-PVC based results 
are presented in Table S1 in the Supplement. 
Association between regional 18F-AV1451 and 
CSF p-tau and t-tau 
We identified 97 ADNI subjects with CSF t-tau 
and p-tau measurements. We observed that CSF p-tau 
was significantly associated with the PVC based 
18F-AV-1451 SUVR in the entorhinal cortex, amygdala, 
fusiform, parahippocampal gyrus, posterior 
cingulate, occipital, lateral temporal, and orbitofrontal 
cortex (P < 0.05; Figure 3). The orbitofrontal cortex 
failed to reach significance in the non-PVC data (P = 
0.07). CSF t-tau was also significantly associated with 
18F-AV-1451 PVC PET in all 8 of these regions. The 
posterior cingulate (P = 0.08) and orbitofrontal cortex 
(P = 0.07) failed to reach significance in the non-PVC 
data. 
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Figure 1. Mean 18F-AV-1451 PET SUVR images with and without partial volume correction in MCI individuals. Mean images were generated by computing the 
mean of images from ApoE ε4 carriers and non-carriers separately. Partial volume corrected images (A) show increased contrast and spatial resolution compared to non-PVC 
images (B). Both PVC and non-PVC images show an interaction effect between sex and ApoE ε4 status. Note that the mean images are averaged over all participants in each 
sex-ApoE ε4 group. 
 
We also analyzed potential ApoE ε4 by sex 
interaction effects in CSF t-tau and p-tau. We found a 
significant ApoE ε4 by sex interaction effect on CSF 
t-tau and p-tau with and without controlling for 
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amyloid in the 97 ADNI subjects with CSF t-tau and 
p-tau measurements (Table 4). Mean CSF t-tau and 
p-tau levels stratified by sex and ApoE ε4 carrier 
status are displayed graphically in Figure 4.  
Discussion and Conclusion 
This cross-sectional analysis provides evidence 
of a significant ApoE ε4 carrier status by sex 
interaction effect on brain tau measured using 
18F-AV-1451 PET in MCI patients. Using 108 ADNI 
participants, we observed a significant ApoE ε4 by sex 
interaction effect (FDR P < 0.1) on 18F-AV-1451 tau 
binding in the entorhinal cortex, amygdala, 
parahippocampal gyrus, posterior cingulate, and 
occipital cortex among MCI individuals. Further, our 
ROI based results suggest that PVC improved PET 
spatial resolution and contrast in this study. 
Specifically, we observe a near but not significant 
ApoE ε4 by sex interaction effect in AV-1451 binding 
without PVC (entorhinal cortex was significant 
without PVC) (Table 2). Also, as a result of applying 
PVC, we are confident that changes in 18F-AV-1451 
reported here are genuine metabolic changes 
associated with ApoE ε4 rather than due to 
volume-related or technical biases.  
 
 
 
Figure 2. Regions with significant ApoE ε4 effect on 18F-AV-1451 SUVR. Bar graphs showing ROIs SUVR (mean with error bars depicting SD) of tau 18F-AV-1451 PET 
imaging between ApoE ε4 carriers and non-carriers in regions with significant ApoE ε4 effect. P value were defined using a two-sample t-test to compare SUVR between ApoE 
ε4 carriers and ApoE ε4 non-carriers in male and female subgroups, and between males and females in ApoE ε4 carrier and ApoE ε4 non-carrier subgroups. *** P < 0.001; ** P 
< 0.01; * P < 0.05. Note: Short significance lines indicate comparison between ApoE ε4 carriers and non-carriers using a two-sample t-test. Long significance lines indicate 
comparison between men and women using a two-sample t-test. 
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Table 3. Effects of ApoE ε4 on 18F-AV-1451 stratified by sex with PVC 
  LS-meana P valueb 
Model Region Women 
ApoE ε4+ 
Women 
ApoE ε4 - 
Men 
ApoE ε4+ 
Men 
ApoE ε4 - 
Women Men ApoE ε4+ ApoE ε4 - 
ε4+ vs ε4 - ε4+ vs ε4 - Women vs Men Women vs Men 
Adjusted for 
global cortical 
amyloid level 
 
Entorhinal Cortex 1.96 1.46 1.48 1.44 <0.001 0.97 0.001 1 
Amygdala 1.79 1.33 1.52 1.40 0.003 0.60 0.13 0.88 
Fusiform 1.39 1.20 1.20 1.20 0.08 1 0.08 1 
Parahippocampal 1.48 1.25 1.26 1.23 0.02 0.98 0.03 1 
Posterior Cingulate 1.46 1.21 1.20 1.21 0.05 1 0.04 1 
Occipital 1.31 1.18 1.14 1.19 0.11 0.63 0.01 1 
Orbital Frontal 1.23 1.17 1.13 1.14 0.61 1 0.14 0.70 
Prefrontal 1.16 1.14 1.09 1.10 0.98 0.99 0.37 0.51 
Superior Frontal 1.17 1.14 1.10 1.08 0.98 0.97 0.69 0.49 
lateral temporal 1.38 1.24 1.23 1,21 0.19 0.98 0.12 0.91 
Parietal 1.25 1.11 1.10 1.08 0.21 0.99 0.13 0.91 
Posterior Precuneus 1.35 1.17 1.21 1.18 0.17 0.98 0.34 1 
Anterior Cingulate 0.94 0.97 0.89 0.88 0.88 0.99 0.75 0.04 
Not adjusted for 
global cortical 
amyloid level 
 
Entorhinal Cortex 2.04 1.41 1.53 1.42 <0.001 0.69 <0.001 1 
Amygdala 1.85 1.29 1.55 1.38 <0.001 0.28 0.10 0.78 
Fusiform 1.45 1.16 1.24 1.18 0.002 0.75 0.06 0.99 
Parahippocampal 1.54 1.21 1.29 1.22 <0.001 0.63 0.02 1 
Posterior Cingulate 1.51 1.18 1.23 1.19 0.003 0.96 0.02 1 
Occipital 1.36 1.15 1.17 1.17 0.003 1 0.01 0.95 
Orbital Frontal 1.24 1.16 1.14 1.13 0.31 1 0.11 0.77 
Prefrontal 1.18 1.13 1.10 1.09 0.73 1 0.30 0.63 
Superior Frontal 1.20 1.12 1.13 1.07 0.49 0.67 0.57 0.71 
Lateral Temporal 1.44 1.20 1.26 1.19 0.01 0.53 0.09 1 
Parietal 1.29 1.08 1.12 1.06 0.01 0.69 0.09 1 
Posterior Precuneus 1.39 1.15 1.23 1.17 0.03 0.79 0.26 0.99 
Anterior Cingulate 0.95 0.97 0.89 0.88 0.97 0.95 0.70 0.05 
a LS-mean indicates the least squares (marginal) means in each ApoE ε4-sex groups after adjusting for age and education. Global cortical amyloid SUVR was also included as 
a covariate in the upper results. 
b All P values correspond to pairwise LS-mean differences after correcting for multiple comparisons using the Tukey-Kramer method. 
 
Table 4. ApoE ε4 by sex interaction effect on CSF t-tau and p-tau in MCI participants 
a β value is coefficient of ApoE ε4 by sex interaction, 95% CI represents the 95% confidence interval of the ApoE ε4 by sex coefficient. 
b P value as defined using a generalized linear model to detect significant ApoE ε4 by sex interaction effect in MCI subjects. Age and education were included as covariates in 
each model. Additional covariates of CSF amyloid or global cortical AV45 were added were added as indicated. 
 
A recently published study analyzed ApoE ε4 by 
sex interaction effects on 18F-AV-1451 PET using 
healthy elderly individuals [28]. The authors found a 
significant ApoE ε4 by sex interaction effect in a 
meta-ROI containing the entorhinal cortex, inferior 
temporal cortex, amygdala, fusiform gyrus, and 
parahippocampal cortex, but no significant ApoE ε4 
by sex interaction effect on the entorhinal cortex 
alone. In contrast to this prior study that investigated 
only cognitively normal individuals, our study 
focused on a cohort with MCI demonstrating that this 
ApoE ε4 by sex interaction on tauopathy persists in 
individuals progressing towards symptomatic AD. 
This result is particularly important when considering 
clinical trials aimed at an MCI cohort. Furthermore, 
our study identifies this interaction using different 
imaging processing methods and additional ROIs, 
suggesting that the ApoE ε4 by sex interaction on 
tauopathy identified by both studies is robust to 
different methodologies within the ADNI cohort. 
Importantly, in the present study we controlled 
for global cortical amyloid load measured by 
18F-AV-45 PET. Recent work shows that amyloid 
might increase brain tau through mechanisms 
involving Sirt3 [29], GSK3β [30, 31] or Cdk5 [32]. In 
imaging studies involving brain tau, it is important to 
control for the potential confounding effects of 
amyloid on tau. In our data, we observe a significant 
ApoE ε4 by sex interaction on AV-1451 PET after 
controlling for global cortical amyloid burden, 
suggesting that the ApoE ε4 allele exerts a 
sex-dependent effect on brain tau, independent of 
amyloidosis. These results are supported by recent 
biochemical studies demonstrating that ApoE ε4 
triggers higher neuronal levels of phospho-tau 
independent of amyloid [33]. Further, transgenic mice 
overexpressing ApoE ε4 exhibit greater hippocampal 
phospho-tau and exhibit deficits in tau clearance 
 CSF t-tau CSF p-tau 
Model Standardized 
β(95%CI) a 
ApoE ε4 x sex 
P value b 
Standardized 
β(95%CI) a 
ApoE ε4 x sex 
P value b 
Not adjusted for global cortical 18F-AV-45 0.35(0.06-0.62) 0.02 0.36(0.08-0.63) 0.01 
Adjusted for CSF amyloid level 0.30(0.03-0.55) 0.03 0.26(0.00-0.52) 0.05 
Adjusted for global cortical 18F-AV-45 (non-PVC) 0.33(0.04-0.60) 0.02 0.33(0.05-0.60) 0.02 
Adjusted for global cortical 18F-AV-45 (PVC) 0.33(0.04-0.60) 0.03 0.33(0.05-0.59) 0.02 
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independent of amyloid pathology [34]. It should be 
noted however that in spite of possible 
amyloid-independent mechanisms, additional 
statistical models analyzing amyloid by sex 
interaction effects suggest that our originally-reported 
ApoE by sex interaction effect on brain tau in the 
occipital cortex may be partly due to amyloid as 
females may be more susceptible to amyloid-induced 
tauopathy in this region (Result S1 in the 
Supplement).  
 
 
Figure 3. Correlations between regional 18F-AV-1451 SUVR and CSF p-tau measurements. Line graphs showing correlation between CSF p-tau (ng/mL) and 
18F-AV-1451 SUVR. Both non-PVC and PVC PET data are shown for ROIs in the entorhinal cortex (A), amygdala (B), fusiform (C), parahippocampus gyrus (D), posterior cingulate 
(E), occipital (F), lateral temporal (G), and orbitofrontal cortex (H). Fitted lines, P-values, and 95% confidence intervals are displayed from linear regression models. 
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Figure 4. ApoE ε4 by sex interaction effects on CSF t-tau, p-tau in MCI individuals. Plots of mean with error bar (standard deviation) showing CSF t-tau (A) and p-tau 
(B) in each sex-ApoE ε4 subgroup. Dashed lines indicate the direction of the ApoE ε4 effect. This graphical depiction of ApoE ε4 by sex interaction effects on CSF t-tau and p-tau 
is supported by statistical results in Table 4.  
 
Our ApoE ε4 and sex-stratified analysis help 
explain the nature of ApoE ε4 by sex interaction effect 
in 4 out of the 5 ROIs with a significant ApoE ε4 by sex 
interaction effect (entorhinal cortex, parahippocampal 
gyrus, posterior cingulate and occipital ROIs). In these 
ROIs, there is no sex difference in 18F-AV-1451 among 
ApoE ε4 non-carriers. However, in ApoE ε4 carriers, 
we observed a significant sex effect (Table 3). This 
suggests that the presence of ApoE ε4 allele is 
associated with significantly higher levels of brain tau 
deposition in females as compared to males.  
As a further measure of clinical relevance of our 
study, we found that 18F-AV-1451 signal in all 5 ROIs 
with significant ApoE ε4 by sex interaction effect is 
also associated with CSF p-tau (Figure 3). Previous 
studies have found an ApoE ε4 by sex interaction 
effect on CSF p-tau, a well-studied biomarker in AD 
[13, 14]. Our data adds to the clinical validity of CSF 
p-tau by elucidating a brain-based correlate. Overall, 
by integrating 18F-AV-1451 PET and CSF p-tau data, 
we find a robust relationship between brain tau and 
biomarker changes outside the brain. 
A possible additional explanation for the sex 
differences identified in our study might be that 
women could be cognitively more resilient to the 
effects of tauopathy. Recent findings suggest that 
women may have on average “younger brain 
predicted age” based on structural brain MRI [35] and 
metabolic brain PET imaging [36]. Similarly, younger 
individuals with autosomal dominant AD show 
markedly increased tauopathy compared to late onset 
AD individuals despite similar degrees of cognitive 
impairment [37]. It is possible then that due to 
increased brain resilience, women with more ApoE ε4 
mediated tauopathy than men can nevertheless 
remain cognitively normal as demonstrated by 
Buckley et al. [28] or mildly impaired as demonstrated 
in our results. In order to further test the hypothesis 
that women may be more resilient to higher loads of 
tauopathy than men in MCI, we refitted our ApoE ε4 
by sex interaction models controlling for MMSE score 
(Table S2 in the Supplement). These results show that 
all five regions with significant ApoE ε4 by sex 
interaction effect in MCI in the original model (Table 
2) are also significant when controlling for MMSE 
score. This analysis further suggests that compared to 
men, women experience greater ApoE ε4-mediated 
tauopathy while remaining at the same level of 
cognitive deficit. Notably the idea that sex differences 
in brain resilience to AD might help explain our 
findings is not mutually exclusive from the idea that 
sex also influences the risk to AD pathology; both sex 
brain differences and ApoE status might carry both 
risks and resilience to neurodegeneration and 
dementia, as well as vascular disease. Further studies 
to disentangle these potentially complex relationships 
are needed. 
This study has clinical implications for precision 
medicine. Our results demonstrate that female ApoE 
ε4 carriers exhibit greater tau accumulation than their 
male counterparts. Several anti-tau clinical trials are 
underway [38, 39]. In designing clinical trials, our 
results suggest that the dosage of anti-tau antibodies 
should be modified by ApoE ε4-sex group. In future 
efforts to validate tau as a quantitative 
endophenotype or clinical outcome measure, studies 
should stratify patient cohorts by ApoE ε4-sex group. 
Likewise, in mechanistic studies exploring 
tau-dependent mechanisms underlying ApoE 
ε4-mediated AD risk, results should be analyzed 
separately in males and females.  
As a limitation to our study, it should be noted 
that our study contained a small percentage (35%) of 
ApoE ε4 carriers. While this proportion is in line with 
previously published studies and the larger ADNI 
cohort [40, 41], possible selection biases may be 
present in our cohort. Future studies should be 
conducted in larger cohorts to minimize selection 
biases. Our study is however balanced in terms of 
proportion of female and male ApoE ε4 carriers 
(females: 36% ApoE ε4 carriers vs males: 35% ApoE ε4 
carriers; P = 0.93, Chi-Square test). 
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Abbreviations 
Aβ: amyloid β; AD: alzheimer’s disease; ADNI: 
alzheimer’s disease neuroimaging initiative; ApoE ε4: 
apolipoprotein E type 4 allele; CSF: cerebrospinal 
fluid; FDR: false discovery rate; FWHM: full width at 
half maximum; GLM: generalized linear model; MCI: 
mild cognitive impairment; MMSE: mini mental state 
examination; MNI: montreal neurological institute; 
MRI: magnetic resonance imaging; NFT: 
neurofibrillary tangles; PET: positron emission 
tomographic; PHF-tau: paired helical filaments of tau; 
p-tau: phosphorylated tau; PVC: partial volume 
correction; ROIs: regions of interest; SAS: statistical 
analysis system; SPM: statistical parametric mapping; 
SUVR: standardized uptake value ratio; t-tau: 
total tau. 
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